Home Drugs Development

Development

Insilico’s Dr Alex Zhavoronkov defines Longevity

The “MMA fighter” of Longevity talks business models, AI drug discovery and working with the right investors. Dr Alex Zhavoronkov is the CEO and co-founder...

AI in peptide discovery: A growing trend

Israeli start-up bags $5 million Series A to drive development of new AI models. Like London buses, we write about one company using artificial intelligence...

AgeX & Juvenescence closer to universal allogeneic cells

AgeX and Juvenescence publish progress in development of hypoimmunogenic cells. Longevity focused life sciences companies, AgeX Therapeutics and Juvenescence , today announced the publication...

Biogen’s Alzheimer’s drug is back from the dead

From Biogen, the first drug to actually slow the decline of Alzheimer's disease, rather than just ameliorate the symptoms, is alive and seeking FDA...

Is the US a slow motion Longevity disaster?

New report finds that sick care in the USA will become increasingly expensive and ineffective as the population ages - the US government needs...

Exciting times – our exclusive with Dr David Sinclair

Q. What does Tony Blair’s reading list and the Longevity.Technology team’s have in common?  A. Dr David Sinclair’s book: Lifespan: Why We Age – and...

Exclusive Profile: Alkahest and blood plasma therapies

Researchers' work with blood plasma may be the key to combating age-related disease When Tony Wyss-Coray discovered that young mouse blood, upon transfusion into older...

New Alzheimer’s drug gives life extension boost

Phase II trials for therapy that combats memory loss, nerve damage and other symptoms of debilitating Alzheimer's disease. New preclinical research has indicated that a...

AI platform accelerates drug discovery time from 3 years to 21 days

The platform, designed by Insilico Medicine, could be a game changer for the pharmaceuticals industry Insilico Medicine, a company using artificial intelligence to accelerate the...

Lifespan boost as world’s first Alzheimer’s vaccine another step closer

This debilitating form of dementia could be halted before devastating symptoms take hold in later life. According to figures from Alzheimer’s Disease International, “Dementia is...

ADVERT

ADVERT

Latest articles

UK doctors told to ignore consumer genetic tests

Royal College of General Practitioners guidance places significant doubt on consumer genetic testing. Consumer interest in genetic testing has grown in popularity in recent years,...

New study shows rapamycin slows Alzheimer’s

A new study from UT Health San Antonio suggests the drug rapamycin may be able to slow the rate of brain-related blood flow decreases. The...

Meet the Startup: Kintell’s take on Alexa Skills

New IoT device focuses on prolonging independence for the broader aging population. While there are many technologies out there designed to help older people who...

The Longevity Week: Addressing global Longevity

A packed week of multidisciplinary events with a global focus on the Longevity challenge. One year ago, the first Longevity Forum event was held in...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.